Ambrx Biopharma Inc - ADR

NYSE:AMAM   10:41:10 AM EDT
12.57
+0.26 (+2.11%)
Products, Regulatory

Ambrx Announces Positive Data On Arx788 For The Treatment Of Her2+ Gastric Cancer Presented At Csco

Published: 10/04/2021 12:42 GMT
Ambrx Biopharma Inc - ADR (AMAM) - Ambrx Announces Positive Data on Arx788 for the Treatment of Her2+ Gastric Cancer Presented at Csco.
Ambrx Biopharma Inc - Arx788 Demonstrated an Orr of 44.4% in Ongoing Ace-gastric-01 Phase 1 Clinical Study in China.
Ambrx Biopharma Inc - Ambrx and Novocodex Recently Dosed First Patient in Ace-gastic-02 Global Phase 2/3 Study.